UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the Securities Exchange Act 1934
Date of Report (date of earliest event reported): November 20, 2009
CAMELOT CORPORATION
(Exact name of registrant as specified in charter)
Colorado 0-8299 84-0691531
(State or other jurisdiction (Commission (IRS Employer
of incorporation) File Number) Identification No.)
730 W. Randolph Street, Suite 600
Chicago, IL 60661
(Address of principal executive offices)
18170 Hillcrest, Suite 100, Dallas, TX 75252
(Former Address of principal executive offices)
312-454-0015
(Issuer's Telephone Number)
Copies to:
Kristen A. Baracy, Esq.
Synergy Law Group, LLC
730 West Randolph Street, Suite 600
Chicago, IL 60661
Phone: 312-454-0015 - Fax: 312-454-0261
Check the appropriate box below if the Form 8-K filing is intended to
simultaneously satisfy the filing obligation of registrant under any of the
following provisions:
[ ] Written communications pursuant to Rule 425 under the Securities Act (17
CFR 230.425)
[ ] Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17
CFR 240.14a-12)
[ ] Pre-commencement communications pursuant to Rule 14d-2(b) under the
Exchange Act (17 CFR 240.14d-2(b))
[ ] Pre-commencement communications pursuant to Rule 13e-4(c) under the
Exchange Act (17 CFR 240.13e-4(c))
CAMELOT CORPORATION
Current Report on Form 8-K
November 23, 2009
ITEM 5.01 CHANGES IN CONTROL OF REGISTRANT
On November 20, 2009, Jeffrey Rochlin (the "Purchaser"), entered into a Stock
Purchase Agreement (the "Purchase") with Danny Wettreich (the "Seller") pursuant
to which the Seller sold 42,753,819 shares of Common Stock of Camelot
Corporation, a Colorado corporation (the "Company"), representing approximately
86.83% of the total issued and outstanding shares of Common Stock of the
Company, for a total purchase price of $8,000.
Upon the closing of the Purchase, the Purchaser acquired 42,753,819 shares of
Common Stock, or approximately 87.33% of the issued and outstanding Common Stock
and attained voting control of the Company.
We are presently authorized to issue 100,000,000 shares of common stock. As of
November 23, 2009, there are 49,236,106 shares of Common Stock issued and
outstanding.
The following table sets forth certain information as of November 23, 2009 with
respect to the beneficial ownership of the Company's outstanding common stock.
Except as otherwise indicated, each of the stockholders listed below has sole
voting and investment power over the shares beneficially owned.
Common Stock Percentage of Common
Name of Beneficial Owner Beneficially Owned Stock Beneficially Owned (1)
------------------------ ------------------ ----------------------------
Jeffrey Rochlin 42,753,819 86.83%
----------
1. Percentage ownership is based on an assumption of 49,236,106 shares of
common stock outstanding as of November 23, 2009. There are no outstanding
options, warrants or other securities convertible into our Common Stock.
2
ITEM 5.02 DEPARTURE OF DIRECTORS OR CERTAIN OFFICERS; ELECTION OF DIRECTORS;
APPOINTMENT OF CERTAIN OFFICERS; COMPENSATORY ARRANGEMENTS OF
CERTAIN OFFICERS
Effective November 20, 2009, Danny Wettreich resigned as President, Chief
Executive Officer, Chairman and Treasurer of the Company and elected Mr. Jeffrey
Rochlin as President, Chief Executive Officer, Chairman and Treasurer of the
Company.
There are no material proceedings known to the Company to which any director,
officer or affiliate of the Company or any owner of record or beneficially of
more than 5% of any class of voting securities of the Company or any affiliate
of such persons is a party adverse to the Company or has a material interest
adverse to the Company. There are no legal proceedings known to the Company that
are material to the evaluation of the ability or integrity of any of the
directors or executive officers.
JEFFREY ROCHLIN
Mr. Rochlin, 40, is a resident of Washington Township, NJ, and a graduate of
University of Hartford, where he earned a degree in accounting. His professional
experience has been primarily in the finance sector, where he has worked as a
finance manager in operations, and senior accountant for a major pharmaceutical
company. Currently, he works for a biotechnology company in its budgeting and
financial reporting sector.
ITEM 8.01 OTHER EVENTS
Concurrent with the Purchase disclosed in Item 1.01 above, the Company changed
the location of its principal executive offices from 18170 Hillcrest, Suite 100,
Dallas, TX 75252 to 730 W. Randolph Street, Suite 600, Chicago, IL 60661 and its
telephone number from 972-612-1400 to 312-454-0015.
ITEM 9.01 FINANCIAL STATEMENTS AND EXHIBITS
None
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the
Registrant has duly caused this report to be signed on its behalf by the
undersigned hereunto duly authorized.
CAMELOT CORPORATION
November 23, 2009 By /s/ Jeffrey Rochlin
---------------------------------
Name: Jeffrey Rochlin
Title: President
3